GLP-1 for Medicaid Patients: State-by-State 2026

Last updated: April 2026

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before starting any treatment.

Affiliate Disclosure: We may earn a commission when you purchase through our links. This does not affect our editorial independence.

Quick Answer

Wegovy has a list price of about $1,350 per month for both the weekly injection pen and the daily pill in 2026 https://www.noom.com/blog/weight-management/wegovy-cost-without-insurance/?srsltid=AfmBOoqGPhQKiQvaAqm_j3HOWpG1WtGmFDc1JklYiYmF5dkbtRd5J5kV.
Without insurance, cash-pay prices for Wegovy typically range from $199–$349 per month for the injection pen and $149–$299 for the pill https://www.noom.com/blog/weight-management/wegovy-cost-without-insurance/?srsltid=AfmBOoqGPhQKiQvaAqm_j3HOWpG1WtGmFDc1JklYiYmF5dkbtRd5J5kV.
Prior authorization is often required for GLP-1 medications, posing challenges for patients and providers https://www.pharmacytimes.com/view/navigating-glp-1-medications-prior-authorization-challenges-and-solutions.
Novo Nordisk has launched lower-cost subscription plans for Wegovy to improve access https://www.powershealth.org/about-us/newsroom/health-library/2026/04/02/wegovy-maker-launches-lower-cost-subscription-plans.

Navigating Medicaid coverage for GLP-1 medications like Wegovy and Ozempic in 2026 involves understanding various factors, including the high list prices, the availability of savings programs, and the complex process of prior authorization. While the list price for Wegovy remains around $1,350 per month for both the injection pen and the newly approved daily pill, cash-pay prices without insurance can be significantly lower, ranging from $199-$349 for the injection and $149-$299 for the pill through specific manufacturer programs https://www.noom.com/blog/weight-management/wegovy-cost-without-insurance/?srsltid=AfmBOoqGPhQKiQvaAqm_j3HOWpG1WtGmFDc1JklYiYmF5dkbtRd5J5kV. Insurance coverage, when available, can reduce monthly costs to $25-$150. Despite these options, patients and healthcare providers often face challenges with prior authorization requirements, which can delay or prevent access to these effective medications. However, manufacturers are introducing new subscription plans to enhance affordability and accessibility, recognizing the shifting landscape of drug pricing and government regulations.

What is the Cost of GLP-1 Medications in 2026?

The cost of GLP-1 medications in 2026 varies widely depending on several factors, including whether you have insurance, the specific medication, and any available savings programs. For Wegovy, a popular GLP-1 medication, the list price is set at approximately $1,350 per month for both the weekly injection pen and the daily pill. This high list price is often a starting point, but what patients actually pay can be much different. We have seen significant changes in how these medications are priced and covered, especially for those without traditional insurance plans.

Understanding List Price vs. Cash Price

The list price of a medication is what the manufacturer suggests, but it is rarely the amount a patient pays out-of-pocket, especially with insurance. For Wegovy, the list price stands at about $1,350 per month for both the weekly injection pen and the daily pill in 2026 https://www.noom.com/blog/weight-management/wegovy-cost-without-insurance/?srsltid=AfmBOoqGPhQKiQvaAqm_j3HOWpG1WtGmFDc1JklYiYmF5dkbtRd5J5kV. However, without insurance, cash-pay prices for Wegovy in 2026 typically range from about $199–$349 per month for the injection pen and $149–$299 for the pill. These lower cash prices are often available through specific manufacturer programs, such as Novo Nordisk's NovoCare Pharmacy, which aims to make the medication more accessible. The introduction of a daily pill version of Wegovy, approved in late 2025, also adds another option for patients, with its own price considerations.

Impact of Insurance Coverage

For those with insurance, the financial burden of GLP-1 medications can be significantly reduced. With insurance, the estimated monthly price for Wegovy is $25–$150 for both the injection pen and the pill https://www.noom.com/blog/weight-management/wegovy-cost-without-insurance/?srsltid=AfmBOoqGPhQKiQvaAqm_j3HOWpG1WtGmFDc1JklYiYmF5dkbtRd5J5kV. This range can vary widely based on the specific insurance plan and its coverage for weight-loss medications. It is crucial for patients to understand their plan's benefits, as many insurance providers have historically been hesitant to cover medications used primarily for weight management. Despite some shifts in this trend, out-of-pocket costs are still common. Factors like your treatment plan, the pharmacy you choose, and whether you qualify for specific savings programs can all affect the final price you pay. Talking with your doctor, pharmacist, or insurance provider is always recommended to get a clear picture of your expected costs.

Comparing Injection vs. Pill Costs

The availability of both injection and pill forms of Wegovy in 2026 offers patients more choices, but also different price points. While the list price is the same for both at $1,350 per month, the cash-pay prices without insurance show a slight difference. The injection pen typically costs between $199 and $349 per month, while the pill form can be found for $149 to $299 per month through Novo Nordisk's NovoCare Pharmacy. This difference might influence a patient's decision, especially if they are paying out-of-pocket. The continued evolution of drug pricing, manufacturer programs, and insurance coverage means that staying informed is key for anyone considering Wegovy for weight management.

How Do Savings Programs and Coupons Help with GLP-1 Costs?

Savings programs and coupons play a vital role in making GLP-1 medications more affordable for many patients, especially given their high list prices. These programs can significantly reduce the out-of-pocket expenses, allowing more people to access necessary treatments. Manufacturers, in particular, have developed various initiatives to help patients manage costs, recognizing the financial barriers that often accompany these effective medications.

Manufacturer Savings Programs for Wegovy

Manufacturer programs are a key avenue for reducing the cost of GLP-1 medications. For Wegovy, Novo Nordisk’s NovoCare Pharmacy offers reduced cash-pay prices for patients without insurance. These programs allow individuals to access Wegovy at a cost significantly lower than its list price. For example, without insurance, the cash-pay price for the Wegovy injection pen can range from $199 to $349 per month, while the pill form can be $149 to $299 per month through NovoCare Pharmacy https://www.noom.com/blog/weight-management/wegovy-cost-without-insurance/?srsltid=AfmBOoqGPhQKiQvaAqm_j3HOWpG1WtGmFDc1JklYiYmF5dkbtRd5J5kV. Beyond these cash prices, specific Wegovy savings programs can save patients up to $55 per fill off the retail price https://www.medicalnewstoday.com/articles/drugs-wegovy-cost. This reduction can be substantial over the course of treatment, making a real difference for those managing chronic conditions. These programs are part of the changing landscape of drug pricing, adapting to government regulations and consumer needs. It is always wise to check the official Wegovy website for the most current savings offers and eligibility requirements.

Ozempic Savings Card Options

Ozempic, another semaglutide-based GLP-1 medication, also provides robust savings options for patients. The Ozempic Savings Card is a valuable resource, particularly for commercially covered patients. With this card, commercially covered patients can pay as little as $25 for up to a 3-month prescription of any dose of Ozempic https://www.ozempic.com/savings-and-resources/save-on-ozempic.html. This program significantly lowers the monthly cost, making long-term treatment more manageable. For patients who are uninsured or self-pay, Ozempic offers a limited-time offer. New patients can pay $25 per month for the first two months of Ozempic 0.25 mg or 0.5 mg https://www.ozempic.com/savings-and-resources/save-on-ozempic.html. This initial discount helps new users get started on their treatment journey without the immediate full financial burden. These savings programs are crucial for improving access to GLP-1 medications, which are highly effective for managing type 2 diabetes and, in the case of Wegovy, weight loss. Patients should always check the official Ozempic website for the latest details on these savings programs.

Prescription Discount Websites and Their Role

Beyond manufacturer-specific programs, prescription discount websites can also offer significant savings. These platforms provide drug coupons that can reduce the cost of many medications, including GLP-1s. It is important to note that these coupons cannot typically be used in conjunction with insurance copays or benefits. However, the discounted price offered by these websites may sometimes be lower than what a patient would pay through their insurance, especially if their plan has high deductibles or limited coverage for specific drugs. Patients should compare prices from various sources—their insurance provider, manufacturer programs, and discount websites—to find the most affordable option. The retail price of Wegovy, for example, is $1349, and these coupons can help bridge the gap between this price and what a patient can afford. The cost of prescription medications is generally higher without insurance, but these resources aim to alleviate that burden.

What Are the Challenges of Prior Authorization for GLP-1s?

Prior authorization is a significant hurdle for patients attempting to access GLP-1 medications, adding layers of bureaucracy to the treatment process. This requirement means that healthcare providers must obtain approval from an insurance company before a medication can be dispensed. The process is designed to ensure that treatments are medically necessary and cost-effective, but it often creates delays and frustration for patients who need these medications.

The Complexity of Prior Authorization

Navigating the prior authorization (PA) process for GLP-1 medications can be exceptionally complex for both patients and healthcare providers https://www.pharmacytimes.com/view/navigating-glp-1-medications-prior-authorization-challenges-and-solutions. Insurance companies often require detailed documentation, including patient medical history, previous treatments attempted, and specific diagnostic criteria that must be met. For GLP-1s, this might include demonstrating a certain BMI, presence of co-morbidities like type 2 diabetes, or a history of failed weight-loss attempts through diet and exercise alone. Gathering all this information, submitting it correctly, and then following up with the insurance company can be a time-consuming administrative burden for physician offices. This administrative load can divert resources from direct patient care and lead to delays in treatment initiation. In some cases, multiple appeals may be necessary if the initial request is denied, further prolonging the process and potentially discouraging patients.

Impact on Patient Access and Adherence

The challenges associated with prior authorization directly impact patient access to GLP-1 medications. Delays in approval can mean patients wait weeks or even months to start a medication that their doctor has deemed medically necessary. This waiting period can exacerbate health conditions, lead to increased frustration, and potentially reduce patient adherence to treatment plans once they finally receive approval. When patients face significant barriers to obtaining their medication, they may become disheartened and less likely to continue pursuing the treatment, even if it is beneficial. The financial aspect also plays a role; even if a medication is eventually covered, the uncertainty and administrative hassle can be overwhelming. This is particularly true for medications like Wegovy, which has a list price of about $1,350 per month, making insurance coverage or other financial assistance critical for most patients https://www.noom.com/blog/weight-management/wegovy-cost-without-insurance/?srsltid=AfmBOoqGPhQKiQvaAqm_j3HOWpG1WtGmFDc1JklYiYmF5dkbtRd5J5kV.

Solutions for Simplifying Prior Authorization

Recognizing the widespread issues with prior authorization, efforts are underway to simplify the process. Technologies and services exist to streamline GLP-1 prior authorization, such as those offered by CoverMyMeds https://www.covermymeds.health/articles/provider-insights/simplify-glp-1-prior-authorization-with-covermymeds. These platforms aim to automate parts of the PA submission, improve communication between providers and payers, and reduce the time spent on administrative tasks. By providing clear guidelines, digital forms, and real-time status updates, these solutions can help healthcare providers submit complete and accurate requests more efficiently, increasing the likelihood of faster approvals. The goal is to reduce the administrative burden on clinics and ensure that patients can access their prescribed GLP-1 medications in a timely manner, ultimately improving health outcomes and reducing the stress associated with obtaining these vital treatments.

What Are the Potential Serious Side Effects of Wegovy?

Wegovy, like any medication, carries the risk of serious side effects that patients and healthcare providers need to be aware of. It is crucial to understand these potential risks before starting treatment to ensure patient safety and make informed decisions. The manufacturer provides detailed safety information, highlighting the most important concerns.

Thyroid Tumors, Including Cancer

One of the most significant serious side effects associated with Wegovy is the possibility of thyroid tumors, including cancer https://www.wegovy.com/obesity/what-to-pay-for-wegovy.html. While studies in rodents showed that Wegovy and similar medicines caused thyroid tumors, including thyroid cancer, it is not yet known if this risk extends to humans. Patients should tell their healthcare provider immediately if they notice any symptoms such as a lump or swelling in their neck, hoarseness, trouble swallowing, or shortness of breath. These symptoms could be indicators of thyroid cancer. It is critically important that patients do not use Wegovy if they or any family members have a history of medullary thyroid carcinoma (MTC), which is a specific type of thyroid cancer, or if they have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), an endocrine system condition that increases cancer risk.

Pancreatitis and Gallbladder Problems

Another serious side effect of Wegovy is inflammation of the pancreas, known as pancreatitis https://www.wegovy.com/obesity/what-to-pay-for-wegovy.html. Patients should stop using Wegovy and contact their healthcare provider right away if they experience severe, persistent pain in their stomach area (abdomen). This pain may or may not be accompanied by nausea or vomiting, and it can sometimes radiate from the abdomen to the back. Pancreatitis is a serious condition that requires immediate medical attention.

Additionally, Wegovy may cause gallbladder problems, including the formation of gallstones https://www.wegovy.com/obesity/what-to-pay-for-wegovy.html. In some cases, gallstones may become severe enough to require surgery. Patients should be vigilant for symptoms such as pain in the upper stomach (abdomen), fever, yellowing of the skin or eyes (jaundice), or clay-colored stools. These signs warrant an immediate call to a healthcare provider. The occurrence of such severe side effects underscores the importance of close medical supervision and prompt reporting of any concerning symptoms while on Wegovy treatment. For more details, see Wegovy maker launches lower-cost subscription plans.

Other Important Safety Considerations

Beyond the most serious risks, patients considering Wegovy must also discuss their full medical history and current medications with their healthcare provider. It is important to disclose any past or current problems with the pancreas or kidneys. Patients with type 2 diabetes and a history of diabetic retinopathy should also inform their doctor. If surgery or other procedures requiring anesthesia or deep sedation are planned, this information is also crucial. For women, Wegovy may harm an unborn baby, so it is recommended to stop using the medication two months before planning a pregnancy. Breastfeeding is not recommended during treatment with Wegovy tablets, and it is unknown if the injectable form passes into breast milk. Wegovy can also affect how other medicines work, particularly those that need to pass through the stomach quickly, as it slows stomach emptying. Patients taking other diabetes medications, such as sulfonylureas or insulin, should also notify their provider. The retail price of Wegovy is $1349, making it a significant investment, and understanding all safety information is part of making an informed decision about treatment.

How Do Manufacturer Subscription Plans Impact Access?

Manufacturer subscription plans are emerging as a key strategy to improve access to high-cost medications like GLP-1s, especially for those who might struggle with traditional insurance coverage or high out-of-pocket expenses. These plans represent a significant shift in how pharmaceutical companies approach drug pricing and patient affordability. By offering direct-to-consumer options, manufacturers aim to bypass some of the complexities of the insurance system and provide more predictable costs for patients.

Novo Nordisk's Lower-Cost Subscription Plans

The maker of Wegovy, Novo Nordisk, has launched lower-cost subscription plans, a development that directly impacts patient access https://www.powershealth.org/about-us/newsroom/health-library/2026/04/02/wegovy-maker-launches-lower-cost-subscription-plans. These plans are designed to make Wegovy more accessible to a broader patient population, including those who are uninsured, underinsured, or whose insurance plans do not cover weight-loss medications. By offering a subscription model, Novo Nordisk aims to provide a more stable and predictable monthly cost, which can be a relief for patients facing the drug's high list price of about $1,350 per month https://www.noom.com/blog/weight-management/wegovy-cost-without-insurance/?srsltid=AfmBOoqGPhQKiQvaAqm_j3HOWpG1WtGmFDc1JklYiYmF5dkbtRd5J5kV. These initiatives are a direct response to the ongoing discussions around drug affordability and the need for more equitable access to life-changing medications. The shift towards subscription plans reflects a broader trend in the pharmaceutical industry to adapt to evolving market demands and regulatory pressures.

Addressing Uninsured and Underinsured Populations

One of the primary goals of these subscription plans is to address the needs of uninsured and underinsured populations. For individuals without comprehensive insurance coverage, the full list price of GLP-1 medications can be prohibitive, making effective treatment out of reach. These lower-cost subscription models can provide a viable pathway for these patients to receive Wegovy. For example, the cash-pay prices for Wegovy without insurance, through programs like Novo Nordisk's NovoCare Pharmacy, already range from $199-$349 for the injection pen and $149-$299 for the pill. Subscription plans could potentially formalize and expand these types of offerings, ensuring more consistent pricing and availability. This development is particularly important as more people seek GLP-1 medications for weight management, a use case that historically has had limited insurance coverage. By making these medications more affordable, subscription plans can help bridge the gap in healthcare access and improve public health outcomes.

The Evolving Landscape of Drug Pricing

The introduction of manufacturer subscription plans is a clear indicator of the ongoing shifts in drug pricing and insurance coverage. As government rules and regulations change, and as public demand for effective weight-loss and diabetes medications grows, pharmaceutical companies are exploring new models to distribute their products. These plans represent an attempt to balance the high costs of drug development with the need for broad patient access. They also offer an alternative to the often-complex prior authorization processes that can delay or deny treatment. While traditional insurance remains a primary method of coverage, these new subscription models provide additional flexibility and options, creating a more dynamic and, hopefully, more accessible market for GLP-1 medications. Staying informed about these evolving programs is essential for patients, healthcare providers, and policymakers alike, as they continue to shape the future of medication access.

Who Should Not Use Wegovy?

Understanding who should not use Wegovy is as crucial as knowing its benefits, as certain medical conditions and personal circumstances can make the medication unsafe. The manufacturer provides clear guidelines and warnings to protect patient health. It is essential for patients to have an open and honest discussion with their healthcare provider about their full medical history before starting Wegovy.

Specific Contraindications for Wegovy

There are clear contraindications for using Wegovy, meaning specific situations where the medication should not be used. First and foremost, you should not use Wegovy if you or any of your family members have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) https://www.wegovy.com/obesity/what-to-pay-for-wegovy.html. This is due to the potential risk of thyroid tumors, including cancer, observed in rodent studies. Similarly, if you have an endocrine system condition known as Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), Wegovy is contraindicated. These conditions significantly increase the risk profile for potential thyroid-related complications.

Another absolute contraindication is a serious allergic reaction to semaglutide or any other ingredients in Wegovy injection or Wegovy tablets https://www.wegovy.com/obesity/what-to-pay-for-wegovy.html. Symptoms of a serious allergic reaction can include swelling of the face, lips, tongue, or throat, severe rash or itching, fainting or feeling dizzy, and trouble breathing or swallowing. If such a reaction occurs, medical attention is required immediately, and the medication should be discontinued. Given that Wegovy has a list price of about $1,350 per month, ensuring that it is safe for the individual before starting treatment is paramount.

Medical Conditions Requiring Caution

Beyond the absolute contraindications, several medical conditions require careful consideration and discussion with a healthcare provider before using Wegovy. Patients who have or have had problems with their pancreas or kidneys should inform their doctor, as Wegovy can exacerbate these issues https://www.wegovy.com/obesity/what-to-pay-for-wegovy.html. Individuals with type 2 diabetes and a history of diabetic retinopathy, a condition affecting the eyes, also need to consult their provider, as GLP-1 medications may have specific considerations for this group. Any planned surgeries or other procedures that use anesthesia or deep sedation should also be disclosed, as Wegovy can affect stomach emptying, which may interact with anesthetic agents. The retail price of Wegovy, which is $1349, underlines the importance of a thorough medical evaluation to ensure its appropriate use.

Pregnancy, Breastfeeding, and Drug Interactions

Pregnant women or those planning to become pregnant should exercise extreme caution. Wegovy may harm an unborn baby, and it is strongly recommended to stop using Wegovy two months before you plan to become pregnant https://www.wegovy.com/obesity/what-to-pay-for-wegovy.html. For breastfeeding mothers, breastfeeding is not recommended during treatment with Wegovy tablets. It is currently unknown if Wegovy, when received through an injection, passes into breast milk, so caution is advised. Furthermore, patients must tell their healthcare provider about all medicines they take, including prescription and over-the-counter drugs, vitamins, and herbal supplements. Wegovy can affect how some medicines work and vice versa. It slows stomach emptying, which can impact medicines that need to pass through the stomach quickly. This is particularly relevant for patients taking other diabetes medications like sulfonylureas or insulin, as adjustments to their dosage might be necessary to prevent low blood sugar. Comprehensive disclosure of all medications and health conditions is vital for safe and effective treatment with Wegovy.

Frequently Asked Questions

What is the list price of Wegovy?

The list price for Wegovy is about $1,350 per month for both the weekly injection pen and the daily pill in 2026 https://www.noom.com/blog/weight-management/wegovy-cost-without-insurance/?srsltid=AfmBOoqGPhQKiQvaAqm_j3HOWpG1WtGmFDc1JklYiYmF5dkbtRd5J5kV. This is the price set by the manufacturer, Novo Nordisk, before any insurance coverage, discounts, or savings programs are applied. While this price is high, what patients actually pay often differs significantly due to various financial assistance options.

Can I get Wegovy without insurance in 2026?

Yes, you can get Wegovy without insurance in 2026, and there are options to help manage the cost. Without insurance, cash-pay prices through programs like Novo Nordisk's NovoCare Pharmacy typically range from $199–$349 per month for the injection pen and $149–$299 for the pill https://www.noom.com/blog/weight-management/wegovy-cost-without-insurance/?srsltid=AfmBOoqGPhQKiQvaAqm_j3HOWpG1WtGmFDc1JklYiYmF5dkbtRd5J5kV. Manufacturer savings programs and prescription discount websites can also help reduce the retail price of $1349.

Are there savings programs for Ozempic?

Yes, Ozempic offers several savings programs. For commercially covered patients, an Ozempic Savings Card allows them to pay as little as $25 for up to a 3-month prescription of any dose https://www.ozempic.com/savings-and-resources/save-on-ozempic.html. Uninsured and self-pay new patients can also pay $25 per month for the first two months of Ozempic 0.25 mg or 0.5 mg, which is a limited-time offer https://www.ozempic.com/savings-and-resources/save-on-ozempic.html.

What are the serious side effects of Wegovy?

Wegovy may cause serious side effects, including possible thyroid tumors, such as cancer, as seen in rodent studies https://www.wegovy.com/obesity/what-to-pay-for-wegovy.html. Other serious side effects include inflammation of the pancreas (pancreatitis) and gallbladder problems like gallstones. Patients should report symptoms like neck lumps, severe stomach pain, fever, or jaundice to their healthcare provider immediately.

Why is prior authorization often needed for GLP-1 medications?

Prior authorization is often needed for GLP-1 medications because insurance companies require approval before covering these high-cost drugs, especially when used for weight loss. This process ensures the medication is medically necessary and meets specific criteria, but it can create significant administrative challenges and delays for both patients and healthcare providers https://www.pharmacytimes.com/view/navigating-glp-1-medications-prior-authorization-challenges-and-solutions.